Analgesic Effect of the QLB-3 for Patients Undergoing a Total Hip Surgery

Total Hip Arthroplasty Clinical Trial

— QLB-3  

Official title:

Analgesic Efficiency of the Type 3 Quadratum Lumborum Block in Patients Undergoing Total Hip Arthroplasty : a Randomized Double Blinded Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04555291
• Other study ID #: 19-PP-13
• Status: Active, not recruiting
• Phase: N/A
• Start date: January 5, 2022
• Est. completion date: October 6, 2024

Study information

• Verified date: March 2024
• Source: Centre Hospitalier Universitaire de Nice
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Total hip arthroplasty (THA) is one of the main elective orthopedic surgery. Recent studies have proven that patients undergoing an elective THA who are part of a fast track surgery program including an opioid free anesthesia (OFA) presented a decrease of mortality and a reduced in-hospital length of stay. Based on the anatomical knowledges, the Quadratus Lumborum Block seems to be an interesting locoregional technique for patients undergoing THA. So far, there is no recommanded locoregional aesthesia in this indication. The investigators hypothezised that QLB would give an efficient analgesia in the 24h following a THA.

Therefor, the study performed a prospective, randomized, double blind trial in the Nice Universitary hospital of Pasteur 2 and in Arnault Tzanck Institute among all patients who underwent THA, comparing a QLB using ropivacaïne 2mg/ml 20ml vs isotonic saline solution 20 ml.The main end-point is the decrease opiod consumption in the 24h following THA.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Est. completion date: October 6, 2024
• Est. primary completion date: October 6, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All adult patients with unilateral programmed total hip prosthesis surgery are included in the absence of inclusion criteria.

• Obligation for all patients to be affiliated with social security

• Patient Informed Consent Signature

Exclusion Criteria:

• chronic opiod consumption

• pregnancy

• mental disorder that prevents the usage of the numeric analog scale

• Contra indications of the realization of QLB

• Local infection

• Allergic to the local anesthesia

• Hemostasis disorder

• Incapacity of giving the consent : individuals under guardianship by court order, or under judicial protection

Related Conditions & MeSH terms

• Total Hip Arthroplasty

Intervention

Drug:
• Ropivacaine injection
Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of ropivacaïne 2 mg/ml

Other:
• NACL
Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of NACL

Locations

Country	Name	City	State
France	CHU de nice - Anesthésie Réanimation	Nice	Alpes-Maritimes
France	Institut Arnaut Tzanck	Nice	Alpes-Maritimes

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Opoïd consumption	The main end point of this study is the decrease of opiod consumption in the 24h following THA.	At 24 Hours
Secondary	morphine equivalent dose	following surgery at rest and in motion	At 48 Hours